

## Cipepofol

## Chemical Properties


CAS No. : 1637741-58-2

Formula: C<sub>14</sub>H<sub>20</sub>O

Molecular Weight: 204.31

Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Cipepofol (HSK3486) is a GABAA receptor agonist with sedative properties and protective effects in a variety of cardiovascular diseases. Cipepofol activates the Sirtuin1 (Sirt1)/Nrf2 pathway and induces apoptosis in cardiomyocytes, and can be used to study myocardial infarction, myocardial ischemia/reperfusion injury, and octopus pot syndrome.
Targets(IC50)	Apoptosis, GABA Receptor, Nrf2, Sirtuin
In vitro	Cipepofol (5 μM; administered before ISO injury; for 6 hours) can attenuate ISO-induced apoptosis in cultured cardiomyocytes in vitro[2].
In vivo	In eighty male C57BL/6 mice (20-24 g, 8-10 weeks old), Cipepofol (100 μl; administered into the abdomen of mice 1 hour before ISO injection) was able to attenuate the increase in serum CK-MB, LDH, and cTnT levels induced by ISO (100 mg/kg; subcutaneous injection; for 2 consecutive days) to create experimental myocardial infarction. Additionally, Cipepofol significantly improved ISO-induced left ventricular systolic and diastolic dysfunction[2].

## Solubility Information

Solubility	DMSO: 255 mg/mL (1248.1 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (16.15 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	4.8945 mL	24.4726 mL	48.9452 mL
5 mM	0.9789 mL	4.8945 mL	9.789 mL
10 mM	0.4895 mL	2.4473 mL	4.8945 mL
50 mM	0.0979 mL	0.4895 mL	0.9789 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Ming Lu, et al. Ciprofol: A Novel Alternative to Propofol in Clinical Intravenous Anesthesia? Biomed Res Int. 2023 Jan 19:2023:7443226.

Yunzhao Yang, et al. Ciprofol attenuates the isoproterenol-induced oxidative damage, inflammatory response and cardiomyocyte apoptosis. Front Pharmacol. 2022 Nov 22:13:1037151.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481